Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.83 |
| ▸ | PLK1 | P53350 | 16/20 | 0.83 |
| ▸ | BRDT | Q58F21 | 10/20 | 0.83 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.80 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.80 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.80 |
| ▸ | CLK2 | P49760 | 3/20 | 0.80 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.80 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.80 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.80 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.80 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.80 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.80 |
| ▸ | TAF1 | P21675 | 3/20 | 0.80 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.80 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.80 |
| ▸ | EGFR | P00533 | 2/20 | 0.80 |
| ▸ | FES | P07332 | 2/20 | 0.80 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619179 | 1.00 | BRD4 (0.83) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL10098799 | 0.93 | PLK1 (0.75) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL617519 | 0.93 | PLK1 (0.75) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL13611485 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL2397131 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL4299436 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL619364 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL618641 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL10098781 | 0.90 | PLK1 (0.69) | BRD4PLK1BRDTPLK3ALK | |
| SCHEMBL4076050 | 0.89 | PLK1 (0.86) | BRD4PLK1BRDTPLK3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | BRD4 555/4885PLK1 109/4885BRDT 783/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885PLK1 110/4885BRDT 789/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | BRD4 614/4885PLK1 110/4885BRDT 789/4885 |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 644/4885PLK1 117/4885BRDT 766/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885PLK1 110/4885BRDT 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.